These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15476151)

  • 1. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence.
    Bardou M; Barkun AN; Ghosn J; Hudson M; Rahme E
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):880-7. PubMed ID: 15476151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS; Nourjah P; Grosser SC; Graham DJ
    Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
    Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
    Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
    Harris RE; Beebe-Donk J; Alshafie GA
    Int J Biol Sci; 2007 Jun; 3(5):328-34. PubMed ID: 17589567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
    Schaefer M; DeLattre M; Gao X; Stephens J; Botteman M; Morreale A
    Curr Med Res Opin; 2005 Jan; 21(1):47-60. PubMed ID: 15881475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
    Moride Y; Ducruet T; Rochon S; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
    Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
    Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
    Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE; Berlin JA; Reilly M; Jaskowiak J; Kishel L; Chittams J; Strom BL
    Ann Intern Med; 2005 Feb; 142(3):157-64. PubMed ID: 15684203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.